A randomised, prospective, parallel and open label study to compare efficacy and safety of single dose versus double dose intra-articular platelet rich plasma in patients of osteoarthritis knee

Samridhy Goklaney; Iqbal Singh Ghai; Gurpreet Kaur Randhawa; Kanwaljit Kaur

doi:10.18203/2319-2003.ijbcp20263775

Authors

Samridhy Goklaney Department of Pharmacology, Government Medical College, Amritsar, Punjab, India
Iqbal Singh Ghai Department of Orthopaedics, Government Medical College, Amritsar, Punjab, India
Gurpreet Kaur Randhawa Department of Pharmacology, Government Medical College, Amritsar, Punjab, India
Kanwaljit Kaur Department of Transfusion Medicine, Government Medical College, Amritsar, Punjab, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20263775

Keywords:

Knee osteoarthritis, Platelet-rich plasma, Western Ontario and McMaster Universities osteoarthritis index, Visual analogue scale

Abstract

Background: Knee osteoarthritis (OA) is a leading cause of chronic pain, disability and impaired quality of life worldwide, with a rapidly increasing burden in the aging population. Conventional therapies primarily provide symptomatic relief and fail to alter disease progression. Platelet-rich plasma (PRP), an autologous biologic has emerged as a promising regenerative therapy. However, the optimal dosing strategy particularly the comparative efficacy of single versus multiple injections remains uncertain.

Methods: This randomized, prospective, parallel, open-label study evaluated 70 patients with Kellgren–Lawrence grade I–III knee OA at a tertiary care center in North India. Participants were randomized into two groups: Group A received a single intra-articular PRP injection (10 ml) while Group B received two PRP injections (10 ml each) administered three weeks apart. Patients were followed up at 21, 60 and 90 days. Clinical outcomes were assessed using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Safety was monitored through adverse event reporting.

Results: Both groups demonstrated statistically significant improvements in VAS and WOMAC scores over the 90-day follow-up period (p<0.001). Double-dose PRP group showed greater reductions in VAS scores and superior improvement in WOMAC parameters compared to the single-dose group (p<0.001). PRP therapy was well tolerated with only minor and self-limiting adverse events.

Conclusion: Intra-articular PRP is a safe and effective treatment modality for knee OA. A double-dose regimen offers superior outcomes compared to a single-dose approach. These findings highlight the importance of dosing strategy in optimizing PRP therapy and support the use of repeated injections for improved patient outcomes.

References

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.

Ashkavand Z, Malekinejad H, Vishwanath BS. The pathophysiology of osteoarthritis. J Pharm Res. 2013;7(1):132–8.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–62.

Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.

Moretti L, Maccagnano G, Coviello M, Cassano GD, Franchini A, Laneve A, et al. Platelet rich plasma injections for knee osteoarthritis treatment: a prospective clinical study. J Clin Med. 2022;11(9):2640.

Patel S, Gahlaut S, Thami T, Chouhan DK, Jain A, Dhillon MS. Comparison of conventional dose versus superdose platelet-rich plasma for knee osteoarthritis: a prospective, triple-blind, randomized clinical trial. Orthop J Sports Med. 2024;12(2):23259671241227863.

Tavassoli M, Janmohammadi N, Hosseini A, Khafri S, Esmaeilnejad-Ganji SM. Single- and double-dose of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: a randomized controlled trial. World J Orthop. 2019;10(9):310–26.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–32.

Ebrahimzadeh MH, Makhmalbaf H, Birjandinejad A, Keshtan FG, Hoseini HA, Mazloumi SM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Persian speaking patients with knee osteoarthritis. Arch Bone Jt Surg. 2014;2(1):57–62.

Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S240–52.

Uppsala Monitoring Centre. The use of the UMC system for standardised case causality assessment. Uppsala: Uppsala Monitoring Centre; 2018. Available from: https://who-umc.org/media/u4gjgxvv/who-umc-causality-assessment_new-logo.pdf Accessed on 03 April 2026.

Bansal H, Leon J, Pont JL, Wilson DA, Bansal A, Agarwal D, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long term clinical efficacy. Sci Rep. 2021;11:3971.

Raeissadat SA, Ghazi Hosseini P, Bahrami MH, Salman Roghani R, Fathi M, et al. The comparison effects of intra-articular injection of platelet-rich plasma (PRP), plasma rich in growth factor (PRGF), hyaluronic acid (HA), and ozone in knee osteoarthritis: a one year randomized clinical trial. BMC Musculoskelet Disord. 2021;22:134.

Felson DT. Osteoarthritis as a disease of mechanics. Osteoarthritis Cartilage. 2013;21(1):10–5.

Zhao W, Chen L, Wang D, Wei X. Comparison of clinical efficacy of sequential and single intra-articular injection of platelet-rich plasma in treatment of early/mid-stage knee osteoarthritis. Front Med (Lausanne). 2025;12:1707979.

Kavadar G, Demircioglu DT, Celik MY, Emre TY. Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: a randomized prospective study. J Phy Therapy Sci. 2015;27(12):3863-7.

Gupta P, Jamra A, Prakash S, Gupta S, Bharti A. Evaluating the efficacy of platelet-rich plasma in treating primary knee osteoarthritis: a prospective interventional study. Cureus. 2024;16(10):e71415.

Fernández-Fuertes J, Arias-Fernández T, Acebes-Huerta A, Álvarez-Rico M, Gutiérrez L. Clinical response after treatment of knee osteoarthritis with a standardized, closed-system, low-cost platelet-rich plasma product: 1-year outcomes. Orthop J Sports Med. 2022;10(3):23259671221076496.

Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration: a meta-analysis of randomized controlled trials. Am J Sports Med. 2025;53(3):745–54.

Wang C, Yao B. Efficacy and safety of platelet-rich plasma injections for the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2025;30:992.